<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35925072</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2731-7099</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Innere Medizin (Heidelberg, Germany)</Title><ISOAbbreviation>Inn Med (Heidelb)</ISOAbbreviation></Journal><ArticleTitle>[The value of COVID-19 vaccination in the context of Long-COVID].</ArticleTitle><Pagination><StartPage>840</StartPage><EndPage>850</EndPage><MedlinePgn>840-850</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00108-022-01368-y</ELocationID><Abstract><AbstractText>There are currently no strategies available on how to deal with Long-COVID (COVID "coronavirus disease"). COVID-19 vaccination could be both a&#xa0;preemptive and a&#xa0;therapeutic option for the future. The evaluation of the available studies is complicated by varying definitions. There are, however, indications that (complete) COVID-19 vaccination is able not only to prevent symptomatic infection but also to reduce the risk of Long-COVID. In some patients with Long-COVID, symptoms are modified after (first and/or second) COVID-19 vaccination; however, there is no clear evidence for a&#xa0;real therapeutic effect on Long-COVID.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauernfeind</LastName><ForeName>Stilla</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r Krankenhaushygiene und Infektiologie, Universit&#xe4;tsklinikum Regensburg, Franz-Josef-Strau&#xdf;-Allee&#xa0;11, 93053, Regensburg, Deutschland. stilla.bauernfeind@ukr.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Klinische Mikrobiologie und Hygiene, Universit&#xe4;tsklinikum Regensburg, Regensburg, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Stellenwert der COVID-19-Impfung im Kontext von Long-COVID.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Inn Med (Heidelb)</MedlineTA><NlmUniqueID>9918384885306676</NlmUniqueID><ISSNLinking>2731-7080</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Strategien zum Umgang mit Long-COVID (COVID &#x201e;coronavirus disease&#x201c;) sind bislang nicht verf&#xfc;gbar. Eine der aktuell gepr&#xfc;ften Optionen ist die COVID-19-Impfung, sowohl pr&#xe4;ventiv als auch therapeutisch. Die Bewertung der vorhandenen Studien ist durch uneinheitliche Definitionen erschwert. Es gibt jedoch Hinweise, dass die (vollst&#xe4;ndige) COVID-19-Impfung nicht nur die symptomatische Infektion verhindern kann, sondern auch das Risiko f&#xfc;r Long-COVID bei Durchbruchinfektionen zu reduzieren vermag. Bei Patienten mit Long-COVID f&#xfc;hrt die anschlie&#xdf;ende (einfache und/oder zweifache) COVID-19-Impfung teilweise zu einer Symptommodifikation, die bisweilen nur passager ist. Ein therapeutischer Effekt kann aus der vorliegenden Evidenz allerdings nicht sicher abgeleitet werden.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breakthrough infection</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccination</Keyword><Keyword MajorTopicYN="N">Long COVID/prevention</Keyword><Keyword MajorTopicYN="N">Long COVID/therapy</Keyword><Keyword MajorTopicYN="N">&#x201e;Severe acute respiratory syndrome coronavirus type&#xa0;2&#x201c; (SARS-CoV-2)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35925072</ArticleId><ArticleId IdType="pmc">PMC9261894</ArticleId><ArticleId IdType="doi">10.1007/s00108-022-01368-y</ArticleId><ArticleId IdType="pii">10.1007/s00108-022-01368-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (2021) A clinical case definition of post COVID-19 condition by a&#xa0;Delphi consensus, 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Zugegriffen: 29. Apr. 2022</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE) (2020) Scottish intercollegiate guidelines network (SIGN) and royal college of general practitioners (RCGP). COVID-19 rapid guideline: managing the long-term effects of COVID-19. https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742. Zugegriffen: 29. Apr. 2022</Citation></Reference><Reference><Citation>Koczulla AR, Ankermann T, Behrends U, Berlit P, B&#xf6;ing S, Brinkmann F, Franke C, Gl&#xf6;ckl R, Gogoll C, Hummel T, Kronsbein J, Maibaum T, Peters EMJ, Pfeifer M, Platz T, Pletz M, Pongratz G, Powitz F, Rabe KF, Scheibenbogen C, Stallmach A, Stegbauer M, Wagner HO, Waller C, Wirtz H, Zeiher A, Zwick R (2021) S1-Leitlinie Post-COVID/Long-COVID. https://www.awmf.org/uploads/tx_szleitlinien/020-027l_S1_Post_COVID_Long_COVID_2021-07.pdf. Zugegriffen: 30. Apr. 2021</Citation></Reference><Reference><Citation>Harrison S, Walters B, Simmons Z, Cook M, Clark R (2022) The effectiveness of vaccination against long COVID; A rapid evidence briefing. https://ukhsa.koha-ptfs.co.uk/cgi-bin/koha/opac-retrieve-file.pl?id=fe4f10cd3cd509fe045ad4f72ae0dfff. Zugegriffen: 23. Apr. 2022</Citation></Reference><Reference><Citation>The Public Health Agency of Canada (2022) Are there clinically significant interactions between COVID-19 vaccination and post-COVID-19 condition (long COVID)? https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases/2019-novel-coronavirus-infection/canadas-reponse/summaries-recent-evidence/evidence-brief-associations-safety-covid-19-vaccination-post-condition/evidence-brief-associations-safety-covid-19-vaccination-post-condition.pdf. Zugegriffen: 23. Apr. 2022</Citation></Reference><Reference><Citation>Ledford H. Do vaccines protect against long COVID? What the data say. Nature. 2021;599:546&#x2013;548. doi: 10.1038/d41586-021-03495-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03495-2</ArticleId><ArticleId IdType="pubmed">34815580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D, Kaphan E, Weber S, et al. Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. Int J Infect Dis. 2021;113:23&#x2013;25. doi: 10.1016/j.ijid.2021.09.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.079</ArticleId><ArticleId IdType="pmc">PMC8487460</ArticleId><ArticleId IdType="pubmed">34614444</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter AG, Shields AM, Karim A, et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin Exp Immunol. 2021;205:99&#x2013;105. doi: 10.1111/cei.13623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13623</ArticleId><ArticleId IdType="pmc">PMC8239842</ArticleId><ArticleId IdType="pubmed">34082475</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J-M, Monsalve DM, Rojas M, et al. Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun. 2021;4:100091. doi: 10.1016/j.jtauto.2021.100091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100091</ArticleId><ArticleId IdType="pmc">PMC7920824</ArticleId><ArticleId IdType="pubmed">33681751</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy WJ, Longo DL. A possible role for anti-idiotype antibodies in SARS-coV-2 infection and vaccination. N Engl J Med. 2022;386:394&#x2013;396. doi: 10.1056/NEJMcibr2113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr2113694</ArticleId><ArticleId IdType="pubmed">34818473</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur JM, Forrest JC, Boehme KW, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE. 2021;16:e0257016. doi: 10.1371/journal.pone.0257016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257016</ArticleId><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Haran JP, Bradley E, Zeamer AL, et al. Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight. 2021;6:e152346. doi: 10.1172/jci.insight.152346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.152346</ArticleId><ArticleId IdType="pmc">PMC8564890</ArticleId><ArticleId IdType="pubmed">34403368</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, et al. Gut microbiota dynamics in a&#xa0;prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Katella K (2021) Why vaccines may be helping some with long COVID. https://www.yalemedicine.org/news/vaccines-long-covid. Zugegriffen: 15. Mai 2022</Citation></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-coV-2 infection in UK users of the COVID symptom study app: a&#xa0;prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55. doi: 10.1016/S1473-3099(21)00460-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y (2022) Long COVID after breakthrough SARS-CoV&#x2011;2 infection. https://www.nature.com/articles/s41591-022-01840-0. Zugegriffen: 29. Mai 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman B, Viwattanakulvanid P, Dzulhadj A, Oo AC, Patricia K, Pongpanich S (2022) Effect of full vaccination and post-COVID olfactory dysfunction in recovered COVID-19 patient. A retrospective longitudinal study with propensity matching. http://medrxiv.org/lookup/doi/10.1101/2022.01.10.22269007. Zugegriffen: 16. Apr. 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.10.22269007</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjam SS, Balhara YPS, Kumar P et al (2021) Assessment of post COVID-19 health problems and its determinants in north India: a descriptive cross section study. http://medrxiv.org/lookup/doi/10.1101/2021.10.03.21264490. Zugegriffen: 13. Apr. 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.03.21264490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bosworth ML, King S et al (2022) Risk of Long Covid in people infected with SARS-CoV&#x2011;2 after two doses of a&#xa0;COVID-19 vaccine: community-based, matched cohort study. http://medrxiv.org/lookup/doi/10.1101/2022.02.23.22271388. Zugegriffen: 15. Mai 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.23.22271388</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H et al (2022) Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a&#xa0;cross-sectional study of patients tested between March 2020 and November 2021. http://medrxiv.org/lookup/doi/10.1101/2022.01.05.22268800. Zugegriffen: 13. Apr. 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.05.22268800</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon MA, Luginbuhl RD, Parker R (2021) Reduced incidence of long-COVID symptoms related to administration of COVID-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. http://medrxiv.org/lookup/doi/10.1101/2021.11.17.21263608. Zugegriffen: 13. Apr. 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21263608</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;162. doi: 10.1016/j.bbi.2022.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D et al (2022) Prevalence, characteristics, and predictors of long COVID among diagnosed cases of COVID-19. http://medrxiv.org/lookup/doi/10.1101/2022.01.04.21268536. Zugegriffen: 13. Apr. 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.04.21268536</ArticleId><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med. 2021;174:1334&#x2013;1336. doi: 10.7326/M21-1976.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-1976</ArticleId><ArticleId IdType="pmc">PMC8252827</ArticleId><ArticleId IdType="pubmed">34029484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaber TA-ZK, Ashish A, Unsworth A, Martindale J Are mRNA covid 19 vaccines safe in long covid patients? A health care workers perspective. https://www.bjmp.org/content/are-mrna-covid-19-8. 9. vaccines-safe-long-covid-patients-health-care-workers-perspective. Zugegriffen: 13. Apr. 2022</Citation></Reference><Reference><Citation>Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines. 2022;10:652. doi: 10.3390/vaccines10050652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M, Pijnenburg L, Chatelus E, et al. Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study. Vaccines. 2021;10:46. doi: 10.3390/vaccines10010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10010046</ArticleId><ArticleId IdType="pmc">PMC8781023</ArticleId><ArticleId IdType="pubmed">35062706</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V&#x2011;T, Perrodeau E, Saldanha J, Pane I, Ravaud P (2021) Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the compare e&#x2011;cohort in France. https://www.ssrn.com/abstract=3932953. Zugegriffen: 13. Apr. 2022</Citation></Reference><Reference><Citation>Wanga V, Chevinsky JR, Dimitrov LV, et al. Long-term symptoms among adults tested for SARS-CoV-2&#x2014;United States, January 2020&#x2013;April 2021. Mmwr Morb Mortal Wkly Rep. 2021;70:1235&#x2013;1241. doi: 10.15585/mmwr.mm7036a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7036a1</ArticleId><ArticleId IdType="pmc">PMC8437054</ArticleId><ArticleId IdType="pubmed">34499626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Salamun J, et al. Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV-2. J Gen Intern Med. 2022;37:1585&#x2013;1588. doi: 10.1007/s11606-022-07443-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07443-2</ArticleId><ArticleId IdType="pmc">PMC8863092</ArticleId><ArticleId IdType="pubmed">35194744</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker HR, Gulea C, Koteci A, et al. GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study. BMJ. 2021 doi: 10.1136/bmj-2021-065834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-065834</ArticleId><ArticleId IdType="pmc">PMC8715128</ArticleId><ArticleId IdType="pubmed">34965929</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, De Martino M, Palese A, et al. Post-COVID-19 syndrome and humoral response association after one year in vaccinated and unvaccinated patients. Clin Microbiol Infect. 2022 doi: 10.1016/j.cmi.2022.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.03.016</ArticleId><ArticleId IdType="pmc">PMC9279256</ArticleId><ArticleId IdType="pubmed">35842022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky JP, Govindarajulu U, Bagiella E et al (2022) Association of vaccination with the persistence of post-COVID symptoms. https://link.springer.com/10.1007/s11606-022-07465-w. Zugegriffen: 12. Mai 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07465-w</ArticleId><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference><Reference><Citation>Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination. J Infect. 2021;83:381&#x2013;412. doi: 10.1016/j.jinf.2021.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.05.035</ArticleId><ArticleId IdType="pmc">PMC8164507</ArticleId><ArticleId IdType="pubmed">34062184</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187&#x2013;2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385:1172&#x2013;1183. doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100899. doi: 10.1016/j.eclinm.2021.100899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100899</ArticleId><ArticleId IdType="pmc">PMC8141371</ArticleId><ArticleId IdType="pubmed">34036253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Couzin-Frankel J, Vogel G. Vaccines may cause rare, Long Covid&#x2013;like symptoms. Science. 2022;375:364&#x2013;366. doi: 10.1126/science.ada0536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.ada0536</ArticleId><ArticleId IdType="pubmed">35084966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gie&#xdf;elmann K, Martin M. Post-Vac-Syndrom: Seltene Folgen nach Impfung. Dtsch Arztebl. 2022;119(19):A-862&#x2013;B-714.</Citation></Reference><Reference><Citation>Massey D, Berrent D, Akrami A et al (2021) Change in symptoms and immune response in people with post-acute sequelae of SARS-Cov&#x2011;2 infection (PASC) after SARS-Cov&#x2011;2 vaccination. http://medrxiv.org/lookup/doi/10.1101/2021.07.21.21260391. Zugegriffen: 13. Apr. 2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.21.21260391</ArticleId></ArticleIdList></Reference><Reference><Citation>University of Oxford (2021) New research studies to help diagnose and treat Long COVID funded by NIHR; Impact of COVID-19 vaccination on preventing Long COVID: a&#xa0;population-based cohort study using linked NHS data. https://www.ox.ac.uk/news/2021-07-19-new-research-studies-help-diagnose-and-treat-long-covid-funded-nihr. Zugegriffen: 30. Apr. 2022</Citation></Reference><Reference><Citation>NIH RECOVER (2022) A multi-site observational study of post-acute sequelae of SARS-CoV&#x2011;2 infection in adults. https://recovercovid.org/docs/Adult.Protocol.v5.1.pdf. Zugegriffen: 30. Apr. 2022</Citation></Reference><Reference><Citation>World Health Organization (2021) Global COVID-19 clinical platform case report form (CRF) for post COVID condition (post COVID-19 CRF). https://apps.who.int/iris/bitstream/handle/10665/345298/WHO-2019-nCoV-Post_COVID-19_CRF-2021.1-eng.pdf?sequence=1&amp;isAllowed=y. Zugegriffen: 23. Apr. 2022</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>